Literature DB >> 10214892

Cholesteatoma otitis media with intact ossicular chain.

M Sakagami1, T Seo, M Node, K Fukazawa, M Sone, Y Mishiro.   

Abstract

Thirty-one cases of cholesteatoma with intact ossicular chain were reviewed to examine the extension of cholesteatoma, operation procedures, pre- and postoperative hearing levels, and postoperative condition of the ear drum. They were operated on at Departments of Hyogo College of Medicine and Osaka University Medical School from 1989-1996, which were 20.4% of all of the primary cholesteatoma cases (n = 152). Twelve cases located at attic were operated by atticotomy or canal wall up and scutumplasty, 17 cases located at attic/antrum were operated by canal wall down and reconstruction, and two cases located around stapes were operated through the ear canal. Preoperative hearing level was mild (34.2 +/- 18.4 dB) and postoperative one was slightly improved (28.7 +/- 11.2 dB). In ossicular reconstruction, modified Wullstein type III method showed better hearing gain than Wullstein type I method. Postoperative attic retraction and/or pocket occurred in 15 cases (48.4%), but no recurrent cholesteatoma was found during the present follow-up period. These findings suggested that cholesteatoma with intact ossicular chain showed good postoperative hearing results, but postoperative retraction of the ear drum should be followed up for a long time.

Entities:  

Mesh:

Year:  1999        PMID: 10214892     DOI: 10.1016/s0385-8146(98)00056-x

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  2 in total

1.  Considerations of isolated destruction of the short process of the incus in a case of cholesteatoma.

Authors:  Asim Aslan; Gulay Guclu Aslan
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-01       Impact factor: 2.503

2.  Treatment of cholesteatoma with intact ossicular chain: anatomic and functional results.

Authors:  V Pontillo; F Barbara; V DE Robertis; N Quaranta
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-02       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.